Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Feature
  • Published:

Screening for content—the evolution of high throughput

Despite a poor return on investment thus far, innovations in high-throughput screening are still very much in demand.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Waning drug approvals.
Figure 2: High throughput screening alliances.

Source: Recombinant Capital

Figure 3: A 900-data point profile with Akceli cell microarrays.

Image courtesy of Akceli.

Figure 4: Avidin-rhodamine staining of liver of an intact zebrafish embryo.

Image courtesy Phylonix.

References

  1. Dove, A. Drug screening—beyond the bottleneck. Nat. Biotechnol. 17, 859–863 (1999).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dove, A. Screening for content—the evolution of high throughput. Nat Biotechnol 21, 859–864 (2003). https://doi.org/10.1038/nbt0803-859

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0803-859

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing